A dietary nutrient supplement for promoting regeneration and repair of skeletal muscle and application thereof

Abstract

The present application belongs to the field of food technology, and particularly relates to a dietary nutrition supplement for promoting regeneration and repair of skeletal muscle and application thereof.The dietary nutrition supplement for promoting regeneration and repair of skeletal muscle comprises whey protein isolate and theabrownin as active ingredients, and the mass ratio of the whey protein isolate to the theabrownin in the active ingredients is 1-10:1.The present application further discloses application of the dietary nutrition supplement or a preparation containing the dietary nutrition supplement in preparation of medicines and health products for promoting regeneration and repair of skeletal muscle, reducing blood sugar and promoting generation of skeletal muscle mitochondria.Compared with the prior art, the dietary nutrition supplement provided by the present application can promote regeneration and repair of skeletal muscle, reduce oxidative stress, promote biogenesis of skeletal muscle mitochondria, improve muscle capacity metabolism and promote muscle strength.

Description

TECHNICAL FIELD

[0001] The present application belongs to the field of food technology, and particularly relates to a dietary nutrient supplement for promoting skeletal muscle regeneration and repair and application thereof. BACKGROUND

[0002] Skeletal muscle accounts for about 40% of the total body mass, provides structural support, movement control and energy storage for life activities, and is an important component for maintaining normal physiological functions of the body. Skeletal muscle has considerable plasticity and adaptability, and can respond to sudden muscle injury and acute exercise stimulation by changing its size, structure and function. Therefore, maintaining normal metabolism, size and contraction function of skeletal muscle is a prerequisite for ensuring overall health. The decline in muscle performance is often associated with aging and diseases. Factors that can cause loss of skeletal muscle mass include the following three types: (1) chronic diseases (cachexia), such as diabetes, cancer, chronic obstructive pulmonary disease, AIDS and heart / kidney failure; (2) muscle atrophy, which is caused by denervation, microgravity, immobilization, etc.; (3) aging (sarcopenia). The above factors can cause significant reduction in muscle fiber cross-sectional area, muscle nucleus number, protein content and muscle strength, muscle fatigue and insulin resistance, and further lead to increased mortality in patients.

[0003] So far, exercise is a recognized effective means to enhance muscle mass and function. However, a considerable number of patients with muscle disorders and the elderly are often limited in activity due to disease and physical condition. Therefore, non-exercise treatment has become a research hotspot in this field. Past reports have focused on reducing muscle loss by taking / injecting drugs such as testosterone, estrogen, growth hormone, angiotensin converting enzyme inhibitors and creatine kinase. However, the effect of such drugs is limited, and they have certain toxic side effects. Therefore, it is a new possibility to find specific exogenous dietary nutrient supplements from natural products to slow down muscle atrophy and enhance muscle performance.

[0004] At present, the prior art CN1785223A discloses a drug composition capable of treating myasthenia gravis and muscle atrophy, which comprises ginseng and epimedium, and can significantly enhance muscle strength. The prior art CN105431057A discloses that catechin EGC can increase the level of muscle vascular endothelial growth factor A (VEGF), reduce the level of myostatin, and reduce or improve muscle function. The prior art CN101978958A discloses a nutritional composition composed of EGCG and resveratrol for preventing and treating muscle loss, atrophy and muscle wasting and other related muscle disorders in mammals.

[0005] Although there are many reports on nutrients for enhancing muscle performance, there is no report on whey protein isolate-theaflavins complex coagulation (TW) for treating muscle atrophy and enhancing muscle performance. Although Chinese patent document CN1316245A mentions the use of tea polyphenols and their oxides (tea pigments) for preparing a treatment for muscle diseases, it does not specifically disclose which tea pigments and how to have a good effect, and the examples only mention tea polyphenols. Therefore, the research and product development of whey protein isolate-theaflavins complex coagulation have broad application prospects. The present inventors have carried out long-term research on this basis, thereby completing the present application. SUMMARY

[0006] Based on the fact that there is no relevant research on whether whey protein isolate-theaflavins complex is related to skeletal muscle regeneration and repair in the prior art, the present application provides a dietary nutritional supplement for promoting skeletal muscle regeneration and repair and its application.

[0007] The present application discloses a dietary supplement for promoting skeletal muscle regeneration and repair and mitochondrial generation, which is prepared by using whey protein isolate as the main dietary raw material and adding theaflavins from tea leaves.

[0008] The most important problem in the present application is to solve the problem of the ratio of whey protein isolate and theaflavins and the actual effect.

[0009] The object of the present application is achieved by the following technical solutions.

[0010] The present application provides a dietary nutritional supplement for promoting skeletal muscle regeneration and repair, which comprises whey protein isolate and theaflavins as active ingredients, and the mass ratio of whey protein isolate to theaflavins in the active ingredients is 1-10:1.

[0011] Specifically, in the above technical solution, whey protein isolate is a product further purified from whey protein, and whey protein with more than 90% protein content is called whey protein isolate. Whey protein isolate is a natural dietary source and has various biological functions. Theaflavins are one of the theaflavins derived from dark tea formed by polyphenol oxidation, known as the "soft gold" in dark tea. The special properties of dark tea, which are different from other teas, are mainly due to theaflavins. Theaflavins are mainly composed of polysaccharide residues, protein residues, lipids and brown pigments with multiple benzene rings, and the main functional groups include carboxyl, hydroxyl, amino and methyl groups, etc., which have the properties of phenolic compounds. Theaflavins have strong biological functions and have significant effects in reducing lipids, antioxidant, anti-inflammatory, anticancer, regulating intestinal flora and treating osteoporosis, etc.

[0012] In one embodiment of the present application, the mass ratio of whey protein isolate to theasinensis is 10:1.

[0013] In one embodiment of the present application, the dietary nutritional supplement further comprises a pharmaceutically acceptable excipient.

[0014] In one embodiment of the present application, the excipient is selected from one or more of starch, dextrin, cellulose, cellulose derivatives or oligosaccharides.

[0015] In one embodiment of the present application, the dietary nutritional supplement further comprises stevioside C, vitamin D2, leucine and mineral salt.

[0016] In one embodiment of the present application, the dietary nutritional supplement is composed of the following raw materials by weight: whey protein isolate 10 parts, theasinensis 1 part, stevioside C 0.2-0.8 parts, vitamin D2 0.2-0.8 parts, leucine 0.2-0.8 parts, and mineral salt 5-10 parts.

[0017] In one embodiment of the present application, the dosage form of the dietary nutritional supplement is selected from one of tablets, capsules, granules, pellets or pills.

[0018] In one embodiment of the present application, the active ingredient of the dietary nutritional supplement is a composite coacervate based on whey protein isolate and theasinensis, and the preparation method of the composite coacervate based on whey protein isolate and theasinensis is:

[0019] S1, dissolving whey protein isolate to obtain a whey protein isolate aqueous solution, and dissolving theasinensis to obtain a theasinensis aqueous solution;

[0020] S2, mixing the whey protein isolate aqueous solution and the theasinensis aqueous solution obtained in step S1 to obtain a whey protein isolate-theasinensis mixed solution;

[0021] S3, adding hydrochloric acid to the whey protein isolate-theasinensis mixed solution obtained in step S2 to obtain a composite coacervate based on whey protein isolate and theasinensis.

[0022] In one embodiment of the present application, in step S1, the concentration of the whey protein isolate aqueous solution is 1-10 mg / mL; further, the concentration of the whey protein isolate aqueous solution is 10 mg / mL.

[0023] In one embodiment of the present application, in step S1, the concentration of the theasinensis aqueous solution is 1-10 mg / mL; further, the concentration of the theasinensis aqueous solution is 10 mg / mL.

[0024] In one embodiment of the present application, in step S1, the concentration of the thearubigin aqueous solution and the whey protein isolate aqueous solution is 10 mg / mL.

[0025] In one embodiment of the present application, in step S2, the volume ratio of the whey protein isolate aqueous solution and the thearubigin aqueous solution is 1:1-15:1; further, the volume ratio of the whey protein isolate aqueous solution and the thearubigin aqueous solution is 10:1.

[0026] In one embodiment of the present application, in step S3, after adding hydrochloric acid to the whey protein isolate-thearubigin mixed solution, the pH is adjusted to 3.2-5.6; further, the pH of the whey protein isolate-thearubigin mixed solution is adjusted to 5.5.

[0027] The present application also provides the use of the dietary nutritional supplement for promoting skeletal muscle regeneration and repair in the preparation of a medicine or health care product for promoting skeletal muscle regeneration and repair and promoting skeletal muscle mitochondria generation.

[0028] In one embodiment of the present application, the use of the dietary nutritional supplement for promoting skeletal muscle regeneration and repair in the preparation of a medicine or health care product for promoting C2C12 differentiation, promoting skeletal muscle regeneration and repair and promoting skeletal muscle mitochondria generation.

[0029] In one embodiment of the present application, the instruction manual of the medicine or health care product indicates that the intake of thearubigin is controlled to be 350-450 mg / d.

[0030] Compared with the prior art, the present application has the following advantages and beneficial effects:

[0031] The dietary nutritional supplement provided by the present application can promote the regeneration and repair of skeletal muscle; reduce oxidative stress, promote the biogenesis of skeletal muscle mitochondria, improve muscle capacity metabolism, and promote muscle strength. BRIEF DESCRIPTION OF DRAWINGS

[0032] In order to more clearly illustrate the technical solutions in the embodiments of the present application or the prior art, the following will briefly introduce the drawings needed in the description of the embodiments or the prior art. Obviously, the drawings described below are some embodiments of the present application, and those skilled in the art can also obtain other drawings according to these drawings without creative labor.

[0033] Figure 1 : Morphology of whey protein isolate-thearubigin complex coacervate continuously cultured C2C12 differentiation for 1, 3, 5, and 7 days.

[0034] Figure 2Expression levels of Myod, Myog, and Myhc proteins in myotubes after continuous culture of whey protein isolate-theabrownin complex aggregates at C2C12 differentiation for 3 days.

[0035] Figure 3 Expression levels of Myod, Myog, and Myhc proteins in myotubes after continuous culture of whey protein isolate-theabrownin complex aggregates at C2C12 differentiation for 5 days.

[0036] Figure 4 Expression levels of Myod, Myog, and Myhc proteins in myotubes after 7 days of continuous culture of whey protein isolate-theabrownin complex aggregates differentiated from C2C12.

[0037] Figure 5 The mRNA expression levels of Myod, Myog, Myhc, CS, IDH, and PDHA in whey protein isolate-theabrownin complex aggregates after continuous culture and differentiation into C2C12 at 3, 5, and 7 days.

[0038] Figure 6 The isocitrate dehydrogenase activity, pyruvate content, NAD+ / NADH ratio, NADPH / NADP+ ratio, ATP content, and acetyl-CoA content of whey protein isolate-theabrownin complex aggregates after 2 days of continuous C2C12 differentiation.

[0039] Figure 7 Bcl-2 protein expression level after 2 days of continuous culture of whey protein isolate-theabrownin complex aggregates at C2C12 differentiation. Detailed Implementation

[0040] The present invention will now be described in detail with reference to the accompanying drawings and specific embodiments.

[0041] In the following examples, the whey protein isolate was purchased from Fonterra and had a purity of 92%.

[0042] Example 1: Effects of whey protein isolate-theabrownin complex on C2C12 cell differentiation

[0043] a) Accurately weigh 1.00 g of commercially available whey protein isolate using an analytical balance and dissolve it in 100 mL of water. At this point, the concentration of the whey protein isolate aqueous solution is 10 mg / mL.

[0044] b) Accurately weigh 1.00 g of commercially available theabrownin using an analytical balance and dissolve it in 100 mL of water. At this point, the concentration of the theabrownin aqueous solution is 10 mg / mL.

[0045] c) Prepare a whey protein isolate-theabrownin mixed solution by mixing the above 10 mg / mL whey protein isolate aqueous solution and 10 mg / mL theabrownin aqueous solution at a volume ratio of 10:1.

[0046] d) Adjust the pH of the whey protein isolate-theaflavins mixed solution to 5.6 with hydrochloric acid, and freeze-dry after standing for 4 h to obtain whey protein isolate-theaflavins complex coacervates.

[0047] e) Dilute the whey protein isolate-theaflavins complex coacervate freeze-dried powder to 50 μg / mL with DMEM high-glucose culture medium containing 2% horse serum and 1% double antibodies to obtain a differentiation culture medium.

[0048] f) Use the differentiation culture medium to continuously culture C2C12 cells for 7 days, and take morphology pictures at 1st, 3rd, 5th, and 7th days, respectively, using a microscope.

[0049] The results are shown in Table 1. Figure 1 The C2C12 cells were cultured using 50 μg / mL of whey protein isolate-theaflavins complex coacervate differentiation culture medium and the cell morphology at different time periods was observed, and the blank group was set to culture using the differentiation culture medium with the same volume of PBS instead of the drug. At 1st day, the C2C12 cells presented thin fibers with slight bulging in the middle, and the density was about 40%. There was no obvious difference between the groups. At 3rd day, it was observed that the muscle cell density increased and the cells were tightly attached to the bottom in a shuttle shape. The whey protein isolate-theaflavins complex coacervate group had a small amount of myotube structure at this time, showing the characteristics of the early stage of differentiation. At 5th day, the C2C12 cell density further increased and the cells were in a long shuttle shape. A large number of myotube structures appeared, and the diameter of the myotube increased, and part of the single cells began to fuse, indicating that the cells entered the middle stage of differentiation, and one of the characteristics of this stage was the fusion of mononuclear cells. At 7th day, the C2C12 cells almost covered the bottom, and a large number of mononuclear cells began to fuse, and a large number of multinucleated myotubes appeared, which was the characteristic of the late stage of C2C12 cell differentiation. However, the blank group still contained a large number of mononuclear cells and mononuclear myotubes. This indicates that the whey protein isolate-theaflavins complex coacervate can promote the differentiation of C2C12, promote cell fusion to form multinucleated myotubes, and promote the formation of muscle fibers.

[0050] Example 2:

[0051] a) Accurately weigh 1.00 g of commercially available whey protein isolate with an analytical balance and dissolve it in 100 mL of water, at this time the concentration of the whey protein isolate aqueous solution is 10 mg / mL.

[0052] b) Accurately weigh 1.00 g of commercially available theaflavins with an analytical balance and dissolve it in 100 mL of water, at this time the concentration of the theaflavins aqueous solution is 10 mg / mL.

[0053] c) Mix the above 10 mg / mL whey protein isolate aqueous solution and 10 mg / mL theaflavins aqueous solution according to the volume ratio of 10:1 to prepare a whey protein isolate-theaflavins mixed solution.

[0054] d) adjusting the pH of the whey protein isolate-theaflavin mixture solution to 5.6 with hydrochloric acid, and freeze-drying after standing for 4 h to obtain whey protein isolate-theaflavin complex coacervates.

[0055] e) diluting the whey protein isolate-theaflavin complex coacervate freeze-dried powder to 50 μg / mL with DMEM high glucose culture medium containing 2% horse serum and 1% double antibody to obtain a differentiation culture medium.

[0056] f) using the differentiation culture medium to continuously culture C2C12 cells for 7 days, and performing immunofluorescence staining on C2C12 cells taken at 3, 5, and 7 days, respectively, to evaluate the expression levels of myotube differentiation markers Myod, Myog, and Myhc proteins.

[0057] The results are shown in Figure 2 Myod is an activation marker in myogenic development and regeneration, and is also a marker protein in the early stage of C2C12 cell differentiation. Myod has a helix-loop-helix (bHLH) structure, can recognize the E-box DNA sequence (CANNTG), and endows MRF with sequence specificity in the target gene regulatory region, and forms a heterodimer with members of the ubiquitously expressed bHLH protein E protein family. Myod has the ability to transform fibroblasts into myoblasts. In the early stage of differentiation, Myod mainly promotes the proliferation and preliminary transformation of myoblasts, and cooperates with other myogenic factors, and can also increase the expression of Myod to promote the further differentiation of myoblasts. Figure 2 The expression of Myod in C2C12 cells after 3 days of differentiation culture is shown. Myod is red in color and spherical or oval, with a blue cell nucleus wrapped therein, and C2C12 cells are uniformly distributed, with single nuclei dispersed. It is obviously observed that the expression of Myod in the whey protein isolate-theaflavin complex coacervate group is more than that in the blank control group, which indicates that in the early stage of differentiation, TB can up-regulate the expression of Myod, promote the proliferation of C2C12 cells, and benefit the differentiation of myoblasts into myotubes. Myostatin Myog is a specific muscle transcription factor, and has very similar E-box DNA sequence binding with Myog, so they directly regulate the expression of many identical muscle genes. Myog can regulate the fusion of myoblasts into muscle fibers, which is also a marker change in the middle stage of differentiation. Figure 3The expression of Myog in C2C12 cells at 5 days of differentiation was shown. In the whey protein isolate-theabrownin complex group, Myog was highly expressed, and some cell nuclei fused, forming multinucleated myotubes. This indicates that C2C12 cells were in the mid-differentiation and early fusion stage. In contrast, only a few cells in the blank control group showed fusion, with most remaining in a uniformly dispersed mononuclear state. This suggests that the whey protein isolate-theabrownin complex helps upregulate Myog expression, thereby promoting further cell differentiation and fusion, leading to the transformation of myoblasts into myofibrils, and ultimately into mature muscle tissue. Myosin is the most important component in the muscle contraction mechanism, existing in multiple isoforms, resulting in the diversity of muscle fiber function. Myosin is typically composed of myosin heavy chains and myosin light chains, with the myosin heavy chain (Myhc) determining the functional differences in myosin. Myhc regulates different types of muscle fibers and is also a marker factor for the late differentiation stage of C2C12 cells. Figure 4 The expression of Myhc in C2C12 cells at 7 days of differentiation was shown. The expression level of Myhc in the whey protein isolate-theabrownin complex group was upregulated compared to the blank control group. Numerous nuclei fused tightly, forming multinucleated myotubes with a significant increase in number and volume, characteristic of the late stage of cell fusion. In contrast, the blank control group showed only partial nuclei fusion, forming a small number of myotubes, while a large number of nuclei remained evenly distributed, characteristic of the early stage of fusion. In conclusion, the whey protein isolate-theabrownin complex accelerated the formation of myotubes and muscle fibers in C2C12 cells, promoting muscle regeneration and repair.

[0058] Example 3:

[0059] a) Accurately weigh 1.00 g of commercially available whey protein isolate using an analytical balance and dissolve it in 100 mL of water. At this point, the concentration of the whey protein isolate aqueous solution is 10 mg / mL.

[0060] b) Accurately weigh 1.00 g of commercially available theabrownin using an analytical balance and dissolve it in 100 mL of water. At this point, the concentration of the theabrownin aqueous solution is 10 mg / mL.

[0061] c) Prepare a whey protein isolate-theabrownin mixed solution by mixing the above 10 mg / mL whey protein isolate aqueous solution and 10 mg / mL theabrownin aqueous solution at a volume ratio of 10:1.

[0062] d) Adjust the pH of the above whey protein isolate-theabrownin mixed solution to 5.6 with hydrochloric acid, let it stand for 4 hours, and then freeze-dry to obtain whey protein isolate-theabrownin complex aggregate.

[0063] e) The whey protein isolate-theabrownin complex lyophilized powder was diluted to 50 μg / mL with DMEM high glucose medium containing 2% horse serum and 1% penicillin to obtain differentiation medium.

[0064] f) C2C12 cells were cultured continuously in differentiation medium for 7 days. On days 3, 5 and 7, C2C12 cells were harvested for qRT-PCR to assess the expression levels of myotube differentiation markers Myod, Myog, Myhc and TCA cycle-related genes CS, IDH and PDHA.

[0065] The results are as follows Figure 5 As shown in the figure, two key enzymes of the TCA cycle—citrate synthase (CS), isocitrate dehydrogenase (IDH), and pyruvate dehydrogenase (PDHA)—were selected for qRT-PCR detection. Corresponding marker myogenic differentiation factors were also detected at different time points. Compared with the control group, the expression of Myhc in cells treated with whey protein isolate-theabrownin complex was increased, indicating that the whey protein isolate-theabrownin complex promotes the formation of multinucleated myotubes and myofibrils, accelerating the repair and regeneration of skeletal muscle. Cells treated with whey protein isolate-theabrownin complex also showed higher expression of key enzymes in the TCA cycle than the control group, indirectly indicating the enhancing effect of whey protein isolate-theabrownin complex on skeletal muscle in terms of energy supply.

[0066] Example 4:

[0067] a) Accurately weigh 1.00 g of commercially available whey protein isolate using an analytical balance and dissolve it in 100 mL of water. At this point, the concentration of the whey protein isolate aqueous solution is 10 mg / mL.

[0068] b) Accurately weigh 1.00 g of commercially available theabrownin using an analytical balance and dissolve it in 100 mL of water. At this point, the concentration of the theabrownin aqueous solution is 10 mg / mL.

[0069] c) Prepare a whey protein isolate-theabrownin mixed solution by mixing the above 10 mg / mL whey protein isolate aqueous solution and 10 mg / mL theabrownin aqueous solution at a volume ratio of 10:1.

[0070] d) Adjust the pH of the above whey protein isolate-theabrownin mixed solution to 5.6 with hydrochloric acid, let it stand for 4 hours, and then freeze-dry to obtain whey protein isolate-theabrownin complex aggregate.

[0071] e) The whey protein isolate-theabrownin complex lyophilized powder was diluted to 50 μg / mL with DMEM high glucose medium containing 2% horse serum and 1% penicillin to obtain differentiation medium.

[0072] f) C2C12 cells were cultured continuously in differentiation medium for 2 days, and the isocitrate dehydrogenase activity, pyruvate content and NAD+ / NADH ratio of C2C12 cells were measured.

[0073] The results are as follows Figure 6 As shown. Energy metabolism is closely related to the repair and regeneration of skeletal muscle. C2C12 cells differentiated for 2 days using whey protein isolate-theabrownin complex and other substances were examined, and the pyruvate content, isocitrate dehydrogenase activity, and NAD+ / NADH ratio were measured. Compared with the control group, the ICDH content in cells treated with whey protein isolate-theabrownin complex, TB, and WPI was significantly higher, but there was no significant difference among the three groups. ICDH is one of the key enzymes in the TCA cycle, and its increased content indicates an increase in ATP. Compared with the control group, the PA content in the cytoplasm of cells treated with whey protein isolate-theabrownin complex, TB, and WPI was significantly higher. PA is a tricarbon keto acid produced in the body, which is the final product of glycolysis. In the cytoplasm, it is reduced to lactate for energy, or it enters the mitochondria and is oxidized to acetyl-CoA, entering the tricarboxylic acid cycle and being oxidized to carbon dioxide and water, completing the aerobic oxidation of glucose for energy. TCA cycle-related and oxidative phosphorylation-related indicators reflect the energy metabolism-related benefits of whey protein isolate-theabrownin complex aggregates to C2C12 cells. Active intracellular TCA cycle and oxidative phosphorylation provide more energy for skeletal muscle regeneration and repair, promoting this process.

[0074] Example 5:

[0075] a) Accurately weigh 1.00 g of commercially available whey protein isolate using an analytical balance and dissolve it in 100 mL of water. At this point, the concentration of the whey protein isolate aqueous solution is 10 mg / mL.

[0076] b) Accurately weigh 1.00 g of commercially available theabrownin using an analytical balance and dissolve it in 100 mL of water. At this point, the concentration of the theabrownin aqueous solution is 10 mg / mL.

[0077] c) Prepare a whey protein isolate-theabrownin mixed solution by mixing the above 10 mg / mL whey protein isolate aqueous solution and 10 mg / mL theabrownin aqueous solution at a volume ratio of 10:1.

[0078] d) Adjust the pH of the above whey protein isolate-theabrownin mixed solution to 5.6 with hydrochloric acid, let it stand for 4 hours, and then freeze-dry to obtain whey protein isolate-theabrownin complex aggregate.

[0079] e) The whey protein isolate-theabrownin complex lyophilized powder was diluted to 50 μg / mL with DMEM high glucose medium containing 2% horse serum and 1% penicillin to obtain differentiation medium.

[0080] f) C2C12 cells were cultured continuously in differentiation medium for 2 days, and the expression level of Bcl-2 protein in C2C12 cells was detected by Western Blot.

[0081] The results are as follows Figure 7 As shown, the whey protein isolate-theabrownin complex induced differentiation upregulated Bcl-2 expression, which helped downregulate cytochrome C and caspase-3 expression, thereby inhibiting apoptosis and promoting mitochondrial biogenesis.

[0082] The above description of the embodiments is provided to enable those skilled in the art to understand and use the invention. It will be apparent to those skilled in the art that various modifications can be made to these embodiments, and the general principles described herein can be applied to other embodiments without inventive effort. Therefore, the present invention is not limited to the above embodiments, and any improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the invention should be within the protection scope of the present invention.

Claims

1. A dietary supplement, characterized in that, The active ingredient of the dietary supplement is a complex coagulated product based on whey protein isolate and theabrownin, and the preparation method of the complex coagulated product based on whey protein isolate and theabrownin is as follows: S1. Dissolve whey protein isolate to obtain whey protein isolate aqueous solution, and dissolve theabrownin to obtain theabrownin aqueous solution; S2. Mix the whey protein isolate aqueous solution and the theabrownin aqueous solution obtained in step S1 to obtain a whey protein isolate-theabrownin mixed solution; S3. Add hydrochloric acid to the whey protein isolate-theabrownin mixed solution obtained in step S2 to obtain a complex aggregate based on whey protein isolate and theabrownin. In step S1, the concentration of the whey protein isolate aqueous solution is 1-10 mg / mL, and the concentration of the theabrownin aqueous solution is 1-10 mg / mL. In step S2, the volume ratio of whey protein isolate aqueous solution and theabrownin aqueous solution is 10:1; In step S3, hydrochloric acid is added to the whey protein isolate-theabrownin mixed solution to adjust the pH range to 3.2~5.6; In the complex aggregate based on whey protein isolate and theabrownin, the mass ratio of whey protein isolate to theabrownin is 10:1; The dietary supplement has the effect of promoting skeletal muscle regeneration and repair.

2. The dietary supplement according to claim 1, characterized in that, The dietary supplement also includes pharmaceutically acceptable excipients.

3. A dietary supplement according to claim 2, characterized in that, The excipients are selected from one or more of starch, dextrin, cellulose, cellulose derivatives, or oligosaccharides.

4. A dietary supplement according to claim 1, characterized in that, The dietary supplement also includes stevioside C, vitamin D2, leucine, and mineral salts.

5. A dietary supplement according to claim 1, characterized in that, The dosage form of the dietary supplement is selected from one of the following: tablets, capsules, powders, granules, or pills.

Images